Subscribe

Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS)

CNY25.87 +0.62 (+2.46%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address Baota Bay 225441
Taixing, CN
CEO Fei Cao
Website jumpcan.com
IPO 2001-08-22
ISIN CNE0000018X6

Explore sections of this company profile

Description

Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the full spectrum of pharmaceutical operations, encompassing research, development, production, and marketing. The company's product lines include both traditional Chinese and Western medicines, as well as daily-use chemical products incorporating traditional Chinese medicine, and health supplements rooted in Chinese medical practices. Their diverse range of Chinese and Western pharmaceuticals addresses a wide array of therapeutic areas, such as pediatric care, women's health, respiratory conditions, digestive disorders, and geriatric medicine. Additionally, their development pipeline covers treatments for detoxification, nervous system ailments, anti-infective agents, cardiovascular issues, pain relief, nutritional deficiencies, musculoskeletal problems, and blood clotting management. Beyond medicinal products, Jumpcan also manufactures oral and skin care items. The company's Chinese medicine-based health products are designed to provide benefits like fatigue reduction, anti-aging effects, antioxidant support, and immune system boosting. Headquartered in Taixing, China, the company adopted its current name, Hubei Jumpcan Pharmaceutical Co., Ltd., in March 2015, having previously operated as Hubei Hongcheng General Machinery Co., Ltd.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY25.87 +0.62 (+2.46%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.18
Float Shares
341.27M
Free Float %
37.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.77% -1.40% -0.58% -0.94% +4.84% +4.68% +1.89% -12.82% +51.26% +20.69% +70.46%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
25.87
DCF (Unlevered) 40.97 +58.4%
DCF (Levered) 38.78 +49.9%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
7.80
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -22.4% Q1'26: -20.8% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -30.1% Q1'26: -8.3% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +21.1% Q1'26: +59.0% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +35.0% ★ Q1'26: +39.8% (vs Q1'25)
  • ✓
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +46.6% ★ Q1'26: +46.5% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.4% Q1'26: +0.0% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.37× ★ Q1'26: 0.54× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.19) × ERP
WACC = 97% × Ke + 3% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 40.97 Current price: 25.87
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
3.77B
est: 3.73B (+0.9%)
4.68B
est: 4.68B (0.0%)
5.64B
est: 5.77B (-2.3%)
7.21B
est: 6.92B (+4.2%)
6.94B
est: 6.94B (0.0%)
6.16B
est: 5.85B (+5.5%)
7.63B
est: 7.50B (+1.8%)
9.00B
est: 8.84B (+1.8%)
9.65B
est: 9.65B (+0.0%)
8.02B
est: 8.77B (-8.6%)
6.22B
est: 6.07B (+2.4%)
6.25B
6.25B – 6.25B
+3.0% YoY
6.52B
6.52B – 6.52B
+4.2% YoY
6.88B
6.88B – 6.88B
+5.6% YoY
EBITDA
847.35M
est: 1.11B (-23.4%)
1.16B
est: 1.39B (-16.6%)
1.50B
est: 1.71B (-12.3%)
2.04B
est: 2.05B (-0.5%)
2.04B
est: 2.06B (-1.1%)
1.67B
est: 1.73B (-3.9%)
1.96B
est: 2.22B (-11.7%)
2.56B
est: 2.62B (-2.2%)
3.18B
est: 2.86B (+11.3%)
2.73B
est: 2.83B (-3.5%)
2.48B
est: 1.96B (+27.0%)
2.02B
2.02B – 2.02B
+3.0% YoY
2.10B
2.10B – 2.10B
+4.2% YoY
2.22B
2.22B – 2.22B
+5.6% YoY
EBIT
738.78M
est: 967.15M (-23.6%)
1.04B
est: 1.21B (-14.3%)
1.35B
est: 1.50B (-9.8%)
1.87B
est: 1.79B (+4.1%)
1.80B
est: 1.80B (+0.3%)
1.39B
est: 1.51B (-8.5%)
1.67B
est: 1.94B (-14.0%)
2.25B
est: 2.29B (-1.5%)
2.88B
est: 2.50B (+15.3%)
2.43B
est: 2.49B (-2.6%)
2.17B
est: 1.72B (+26.0%)
1.78B
1.78B – 1.78B
+3.0% YoY
1.85B
1.85B – 1.85B
+4.2% YoY
1.96B
1.96B – 1.96B
+5.6% YoY
Net Income
686.57M
est: 449.44M (+52.8%)
934.18M
est: 1.05B (-11.4%)
1.22B
est: 1.39B (-11.8%)
1.69B
est: 1.87B (-9.8%)
1.62B
est: 1.83B (-11.3%)
1.28B
est: 1.43B (-10.7%)
1.72B
est: 1.73B (-0.7%)
2.17B
est: 2.10B (+3.6%)
2.82B
est: 2.52B (+12.1%)
2.53B
est: 2.69B (-5.9%)
1.78B
est: 1.63B (+9.0%)
1.81B
1.81B – 1.81B
+10.7% YoY
1.92B
1.92B – 1.92B
+6.4% YoY
2.06B
2.06B – 2.06B
+7.2% YoY
SGA
2.35B
est: 1.82B (+29.1%)
2.84B
est: 2.28B (+24.6%)
3.16B
est: 2.81B (+12.2%)
3.90B
est: 3.37B (+15.7%)
3.71B
est: 3.38B (+9.6%)
3.30B
est: 2.85B (+15.8%)
4.03B
est: 3.65B (+10.3%)
4.48B
est: 4.31B (+4.0%)
4.38B
est: 4.71B (-6.9%)
3.39B
est: 3.92B (-13.7%)
2.09B
est: 2.72B (-23.1%)
2.80B
2.80B – 2.80B
+3.0% YoY
2.92B
2.92B – 2.92B
+4.2% YoY
3.08B
3.08B – 3.08B
+5.6% YoY
EPS
0.88
est: 0.49 (+79.6%)
1.17
est: 1.15 (+1.7%)
1.51
est: 1.51 (-0.1%)
2.08
est: 2.04 (+2.0%)
1.99
est: 2.00 (-0.3%)
1.53
est: 1.56 (-1.9%)
1.94
est: 1.89 (+2.8%)
2.44
est: 2.29 (+6.8%)
3.08
est: 2.75 (+12.2%)
2.76
est: 2.92 (-5.5%)
1.93
est: 1.77 (+9.0%)
1.96
1.96 – 1.96
+10.7% YoY
2.09
2.09 – 2.09
+6.4% YoY
2.24
2.24 – 2.24
+7.2% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-28 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-27 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-26 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-25 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-22 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-21 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-20 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-19 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-18 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-15 A 4/5 4/5 4/5 5/5 3/5 3/5 3/5
2026-05-14 A 4/5 4/5 4/5 5/5 3/5 3/5 3/5
2026-05-13 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-05-12 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-05-11 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-05-08 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-05-07 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-05-06 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-04-30 A 4/5 4/5 4/5 5/5 2/5 3/5 4/5
2026-04-29 A 4/5 4/5 4/5 5/5 2/5 3/5 4/5
2026-04-28 A 4/5 4/5 4/5 5/5 2/5 3/5 4/5
2026-04-27 A 4/5 4/5 4/5 5/5 2/5 3/5 4/5
2026-04-24 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-23 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-22 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-21 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-20 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-17 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-16 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
605.58M
OE per share TTM
0.66
Owner's Yield
2.40%
Maintenance CapEx ratio
78.30%
Maint CapEx / Avg PPE
37.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 35 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Global X China Biotech ETF (HKD) 2820.HK 0.96% 769.6K 0.68%
2 JPMorgan Diversified Return Emerging Markets Equity ETF JPEM 0.12% 447.8K 0.44%
3 Invesco FTSE Emerging Markets High Dividend Low Volatility UCITS ETF EMHD.L 0.09% 263.1K 0.49%
4 Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS 0.08% 27.9K 0.65%
5 iShares Emerging Markets Equity Factor ETF EMGF 0.03% 530.4K 0.26%
6 KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L 0.02% 15.9K 0.55%
7 Franklin FTSE China UCITS ETF FLXC.L 0.01% 197.1K 0.19%
8 Dimensional - Emerging Markets Value ETF DFEV 0.01% 145.2K 0.46%
9 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.01% 33.1K 0.44%
10 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 275.8K 0.39%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
415.6K
Shares Outstanding
921.66M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Fei Cao Vice Chairman & GM — male
Hong Quan Yan Deputy GM & Financial Director — male
Jian Hong Xi Accounting Supervisor — —
Qi Hua Zhou Deputy General Manager — male
Qu Rong Huang Director — male
Wei Cao Deputy GM, Board Secretary & Director — male
Wen Zheng Shi Director of Human Resources — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic